Acquired EGFR antagonist resistance is often associated with the activation of bypass signalling pathways typically embedded in tumour cells or the surrounding tissue (Arteaga 2002, Wieduwilt & Moasser 2008, Cathomas et al. 2012, Seshacharyulu et al. 2012). This evidence concerns the gene EGFR and neoplasm.